CRSP Stock Price Today (July 2026) — CRISPR Therapeutics AG Analysis & Key Metrics 2026-07-17
CRISPR Therapeutics AG (CRSP) is trading at $47.78, down 1.63% today (as of July 2026). The stock continues to show pressure below major moving averages, attracting attention from investors looking for Healthcare growth opportunities.
- According to consensus analyst estimates, the 1-year price target is $83.52 (74.8% upside).
- Volatility remains elevated (52.64% annualized), implying wide price swings for short-term traders.
- The fundamental picture, based on the latest financial filings, is nuanced: solid revenue growth (68.60% YoY) alongside significant competitive pressures.
CRSP Stock Analysis: Key Metrics & Valuation (July 2026)
Concise, actionable data for investors
CRISPR Therapeutics AG - Historical Price & Volume
Market Cap
Enterprise Value: $3.61B
P/E Ratio
Forward P/E: -14.56
Revenue Growth
Year over Year
Analyst Target
+74.8% upside potential
Key Investor Questions About CRSP
What investors need to know before buying
Based on current market data, CRSP presents a neutral technical setup with caution warranted fundamentals.
- Technicals say: Neutral (RSI 30.39)
- Fundamentals say: Caution warranted (high leverage concerns)
CRSP's growth trajectory depends on its ability to expand within the Biotechnology sector while managing margin pressures.
- Future growth will depend on performance in core Biotechnology operations.
- The ability to manage competitive pressures will be crucial for sustained growth.
The primary risks for CRSP investors include debt exposure and competitive dynamics in the Biotechnology industry.
- $787.64M in debt could be a headwind in a high-rate environment.
- Fierce competition from established players in Biotechnology.
52-Week Trading Range
Over the past year, CRSP stock traded between $44.12 and $78.48—recovering meaningfully from lows and currently near the higher end. Big swings are likely unless a major catalyst emerges.
Volatility & Risk Profile
With 52.64% annualized volatility and β=1.46, the stock exhibits high sensitivity to market moves—making CRSP suitable for investors comfortable with active risk management.
Institutional & Insider Ownership
High institutional backing, but elevated short interest signals a potential battleground stock.
Analyst Sentiment & Price Targets
Latest News & Headlines
Recent headlines and coverage
Has CRISPR Therapeutics (CRSP) Fallen Far Enough To Look Undervalued?
CRISPR Therapeutics stock has delivered a decline of about 61% over the past five years, yet current valuation checks suggest the shares now sit closer to "about right" territory rather than looking clearly cheap or clearly expensive. The roughly 60.9% five year share price decline points to investors reassessing how much they are willing to pay for CRISPR Therapeutics' long term gene editing opportunity. Strong cash of around US$2.4b that has been highlighted in recent coverage can support...
Do CRISPR Therapeutics' (CRSP) EPS Projections Clarify Its Gene‑Editing Commercialisation Path?
Earlier this week, CRISPR Therapeutics AG drew attention as analysts projected an earnings per share of US$1.10 loss alongside very large year-over-year revenue growth for its upcoming results. This combination of improving earnings expectations and strong sales momentum has sharpened the focus on how the company is progressing in commercialising its gene-editing pipeline. Next, we will examine how the anticipated earnings improvement shapes CRISPR Therapeutics’ investment narrative over the...
CRISPR Therapeutics AG (CRSP) Declines More Than Market: Some Information for Investors
In the latest trading session, CRISPR Therapeutics AG (CRSP) closed at $47.78, marking a -1.63% move from the previous day.
CRISPR Therapeutics (CRSP) Slides For Six Days, Is The Stock Now Cheap?
CRISPR Therapeutics (NasdaqGM:CRSP) has come under pressure after a six day losing streak that cut the stock by about 18%, erasing roughly US$1.1b in market value and drawing attention to its fundamentals. See our latest analysis for CRISPR Therapeutics. The recent six day slide for CRISPR Therapeutics comes on top of weaker momentum over longer periods, with the 30 day share price return down 6.63% and the 1 year total shareholder return down 11.84%. This points to fading enthusiasm and...
Here's Why CRISPR Therapeutics AG (CRSP) Fell More Than Broader Market
CRISPR Therapeutics AG (CRSP) reached $48.57 at the closing of the latest trading day, reflecting a -5.45% change compared to its last close.
Collect 9.8% On VRTX Stock Now, And Still Keep 15% Of Upside
Get paid a guaranteed income on your Vertex shares today, which you keep no matter what, for agreeing to sell them at a higher price if the stock keeps climbing.
CRISPR Therapeutics AG (CRSP) Is a Trending Stock: Facts to Know Before Betting on It
Recently, Zacks.com users have been paying close attention to CRISPR Therapeutics (CRSP). This makes it worthwhile to examine what the stock has in store.
CRISPR Therapeutics AG (CRSP) Stock Dips While Market Gains: Key Facts
CRISPR Therapeutics AG (CRSP) closed the most recent trading day at $53.35, moving 5.31% from the previous trading session.
3 Reasons to Buy CRISPR Therapeutics Stock
The company's innovative qualities may pay rich dividends down the road.
NTLA Surges 38% in a Month: Should You Buy, Sell or Hold the Stock?
Intellia gains 38% in a month as additional positive phase III lonvo-z data and other pipeline progress boost investor optimism.
Frequently Asked Questions
Common investor questions about CRISPR Therapeutics AG
CRISPR Therapeutics AG (CRSP) is currently trading at $47.78. The RSI (14-day) is at 30.4, indicating neutral territory. Wall Street analysts have a consensus "buy" recommendation. The mean analyst price target of $83.52 implies 74.8% upside from current levels. Volatility is high at 52.6% annualized, meaning significant price swings are common. Investors should consider their risk tolerance, investment horizon, and portfolio diversification before making a decision.
Based on current valuation metrics for CRISPR Therapeutics AG (CRSP): The trailing P/E ratio is -7.74, which is below the market average of ~20-22, suggesting the stock may be undervalued relative to peers. The forward P/E is -14.56, lower than the trailing P/E, suggesting analysts expect earnings improvement. Price-to-Book is 2.54. Price-to-Sales is 1146.86. Valuation should be compared to Biotechnology industry peers for context, as different sectors trade at different multiples.
Based on 21 analysts covering CRSP, the consensus price target is $83.52. This represents a 74.8% upside from the current price of $47.78. The range spans from a low target of $44.00 to a high target of $291.00, reflecting varying levels of optimism among analysts. The consensus recommendation is "buy". Note: Analyst price targets are forward-looking estimates and not guarantees of future performance.
CRISPR Therapeutics AG (CRSP) does not currently pay a regular dividend. The company may be reinvesting profits into growth initiatives, or may not yet be profitable enough to distribute earnings to shareholders.
Key risks for CRISPR Therapeutics AG (CRSP) investors include: 1. High volatility (52.6% annualized)—the stock can experience significant daily price swings. 2. Elevated short interest (30.8% of float) suggests significant bearish sentiment. 3. Broader market and macroeconomic risks (interest rates, inflation, geopolitical events). 4. Biotechnology sector-specific competitive pressures. Investors should diversify and consider their risk tolerance before investing.
Here is CRISPR Therapeutics AG's (CRSP) current debt and financial health profile: Total debt stands at $787.64M. The debt-to-equity ratio is 43.41, which is moderate and generally manageable for most companies. The current ratio is 17.96, indicating strong short-term liquidity. The quick ratio is 17.92. The company holds $2.44B in cash and equivalents. Free cash flow is negative at $-260,895,744, which could limit the company's ability to manage debt obligations.